From March next year, businesses shipping between London Heathrow and Tel Aviv will benefit from a dedicated wide-body service courtesy of IAG Cargo. The carrier is replacing its remaining Airbus A321 with wide-body Boeing 777-200s, which will operate twice daily and promise to prove particularly beneficial to Israel’s fast-growing time and temperature-sensitive pharmaceuticals sector. Customers will now benefit from a daily lift of 29 tonnes; representing a net increase of 2500 tonnes in summer 2016 vs the same time this year, an increase of 72%. Alan Dorling, Global Head of Pharmaceuticals & Life Sciences at IAG Cargo, commented: “Tel Aviv is a thriving business centre and it’s also one of the most important regions for the manufacture of pharmaceuticals. Through the additional capacity delivered by the 777-200, we can now offer manufacturers in the region greater lift, helping them, as they look to grow their businesses.” The additional capacity will be particularly beneficial to businesses operating within Tel Aviv’s high-growth pharmaceuticals sector. Israel is a major manufacturer of pharmaceutical products and its total pharmaceuticals market is expected to grow to $2.3bn by 2020[1]. Connecting through IAG Cargo’s London GDP approved Heathrow hub, Israeli drug companies’ benefit from access to 106 Constant Climate approved destinations, including extensive connections to the high-growth pharmaceuticals markets of Latin America.